YIELD10 BIOSCIENCE, INC.: Nasdaq/NYSE listing notice — Yield10 Bioscience receives Nasdaq bid price deficiency notice; faces potential delisting

YIELD10 BIOSCIENCE, INC.

Nasdaq notified Yield10 on Sept 25, 2023 that its common stock closed below $1.00 for 30 consecutive business days.
Company has until March 25, 2024 to regain compliance by achieving $1.00 closing bid for at least 10 consecutive days.
If not compliant by March 25, 2024, Yield10 may qualify for an additional 180-day period subject to meeting other listing standards.
Yield10 is considering options, including a potential reverse stock split, to cure the deficiency.
Stock continues trading on Nasdaq under symbol YTEN while the company pursues compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 25, 2023, Yield10 Bioscience, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance. To regain co

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001121702-23-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.